{"id":1005775,"date":"2026-09-24T11:32:54","date_gmt":"2026-09-24T15:32:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/"},"modified":"2026-09-24T11:32:54","modified_gmt":"2026-09-24T15:32:54","slug":"neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/","title":{"rendered":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst"},"content":{"rendered":"
\n

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) — (247marketnews.com<\/u><\/a>) — NeOnc Technologies Holdings (NASDAQ: NTHI)<\/strong> has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24.<\/p>\n

The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development.<\/p>\n

The most immediate story is NEO100<\/strong>. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produced six-month progression-free survival of 48.9% versus a prespecified 20% benchmark<\/strong>, with a reported median overall survival of 26.09 months. The company said it planned to request a Type B meeting with the FDA to discuss a registrational path.<\/p>\n

That puts regulatory interaction squarely in the spotlight. A September report summarizing Roth’s research says Aschoff expects an FDA Type B End-of-Phase 2 meeting in October and sees potential pivotal-trial starts before the end of 2026. Those are analyst expectations, not FDA commitments or guaranteed timelines.<\/p>\n

Roth’s longer-range model reportedly envisions NEO100 launching in 2029 and NEO212 in 2030, assuming successful clinical development, regulatory approval, financing and commercialization. The two programs target difficult-to-treat central nervous system cancers, including recurrent high-grade astrocytoma, glioblastoma and brain metastases.<\/p>\n

NEO212 is also moving forward. The company reported FDA feedback on chemistry, manufacturing and controls in July, while Phase 1 work established a recommended Phase 2 dose of 610 mg after dose escalation reached its protocol-defined maximum tolerated dose.<\/p>\n

Meanwhile, NeOnc has strengthened its balance sheet for the next leg of development with a $15 million registered direct offering in September. The financing was priced at $4.20 per share, with accompanying warrants carrying a $4.20 exercise price. Roth Capital and A.G.P.\/Alliance Global Partners acted as placement agents.<\/p>\n

The company also recently announced that executives purchased NeOnc shares in the open market following the NEO100 data, while separately redeeming its outstanding Series A convertible preferred stock.<\/p>\n

\n About 24\/7 Market News<\/strong>\n <\/p>\n

In today’s fast-moving markets, visibility is everything and 24\/7 Market News (24\/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company\u2019s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24\/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com<\/u><\/a> to discuss how 24\/7 can help accelerate your company\u2019s visibility and valuation trajectory.<\/p>\n

This is a paid editorial communication intended for informational purposes only. 24\/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here<\/u><\/a>. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.<\/p>\n

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.<\/p>\n

\n CONTACT:<\/strong>
\n
24\/7 Market News
Editor@247mnn.com<\/u><\/a><\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24. The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development. The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produced six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported median overall survival of 26.09 months. The … <\/p>\n

Continue reading “NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1005775","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24. The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development. The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produced six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported median overall survival of 26.09 months. The … Continue reading "NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-24T15:32:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst\",\"datePublished\":\"2026-09-24T15:32:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/\"},\"wordCount\":727,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/\",\"name\":\"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==\",\"datePublished\":\"2026-09-24T15:32:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk","og_description":"DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24. The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development. The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produced six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported median overall survival of 26.09 months. The … Continue reading \"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-24T15:32:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst","datePublished":"2026-09-24T15:32:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/"},"wordCount":727,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/","name":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==","datePublished":"2026-09-24T15:32:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzQyOCM3ODYyMDY4IzUwMDE2MjE5NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-lands-new-coverage-and-roth-sees-potential-2026-trial-catalyst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1005775"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005775\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1005775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1005775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1005775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}